

comprising one or more unboxed residues of the corresponding sequence in at least one table selected from the group consisting of Table 1 and Table 2.

6
13. (Amended) An isolated polypeptide according to claim 8 comprising [at least one of] SEQ ID NO:2, or a subsequence thereof having at least 16 consecutive residues thereof and comprising one or more unboxed residues of the corresponding sequence in Table 2.

7
14. (Amended) An isolated polypeptide according to claim 8 comprising [at least one of] SEQ ID NO:2, or a subsequence thereof having at least 64 consecutive residues thereof and comprising one or more unboxed residues of the corresponding sequence in Table 2.

10
17. (Amended) An isolated polypeptide [made by expressing a recombinant nucleic acid comprising a coding strand encoding a polypeptide] comprising at least one sequence selected from the group consisting of SEQ ID NO:2-6 and [8]10-14, or a subsequence thereof having at least 16 consecutive residues thereof and comprising one or more unboxed residues of the corresponding sequence in at least one table selected from the group consisting of Table 1 and Table 2[, wherein said strand is flanked by fewer than 500 bp of native flanking sequence].

10
18. (Amended) An isolated polypeptide according to claim 17 [made by expressing a recombinant nucleic acid comprising a coding strand encoding a polypeptide] comprising at least one sequence selected from the group consisting of SEQ ID NO:2 -6 and 10-14, or a subsequence thereof having at least 64 consecutive residues thereof and comprising one or more unboxed residues of the corresponding sequence in at least one table selected from the group consisting of Table 1 and Table 2[, wherein said coding strand is flanked by fewer than 500 bp of native flanking sequence].

12
19. (Amended) An isolated polypeptide according to claim 17 [made by expressing a recombinant nucleic acid comprising a coding strand encoding a polypeptide] comprising at least one sequence selected from the group consisting of SEQ ID NO:2 -6 and 10-14[, or a subsequence

55

03
CM
thereof having at least 64 consecutive residues thereof and comprising one or more unboxed residues in Table 2, wherein said strand is flanked by fewer than 500 bp of native flanking sequence and said strand comprises SEQ ID NO:1, or a fragment thereof encoding said subsequence].

In line 8 of each of claims 20-23, please change "aget" to -agent-.

REMARKS

The specification has been amended to change the reference to the priority applications as requested by the Examiner and to delete reference to complex consensus sequences that do not relate to the invention as claimed and would otherwise necessitate a complex amended sequence listing. The claims have been amended to omit fragments of SEQ ID NO:9, to avoid the double patenting and definiteness issues raised by the Examiner. These amendments introduce no new matter.

Any need for a revised sequence listing is believed to be avoided by the foregoing amendments to the specification.

We confirm election of group I. Upon allowability of the product claims of Group I, Applicants request rejoinder of non-elected Group II claims 20-28 and new dependent claims 50-52 (in the case of an elected product claim, rejoinder will be permitted when a product claim is found allowable and the withdrawn process claim depends from or otherwise includes all the limitations of an allowed product claim, per Commissioner Lehman's Notice of February 28, 1996: Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. 103(b)).

The requested language re our priority claims has been adopted in the foregoing amendments.

The inserted table pages have been numbered and the subsequent pages renumbered in the foregoing amendments.

The definiteness issues have been addressed by the foregoing amendments. With regard to claim 8, etc., the reference to Table 1 and 2 are believed to be those intended, although the